Axsome up after FDA grants priority review for Alzheimer's agitation drug

Axsome Therapeutics

31/12/2025 12:35

** Shares of Axsome Therapeutics AXSM.O rise 2.2% to $152 premarket

** Drugmaker says that the U.S. FDA has accepted its marketing application for its drug, AXS-05, to treat Alzheimer's disease agitation

** Agitation in Alzheimer's disease is a common symptom of emotional distress, marked by restlessness, pacing, verbal outbursts, or physical aggression often triggered by pain, changes in routine, confusion, or feeling overwhelmed

** The FDA has granted the application a 'priority review' tag, which is given to drugs that may offer significant improvements in effectiveness or safety for serious conditions

** The health regulator is set to decide on the drug on April 30, 2026 - AXSM

** Up to last close, stock up 75.8% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))